Alnylam Plans Lumasiran Phase III As Market Landscape Gets Competitive

 
• By John Davis

Alnylam will take on the global development and commercialization of investigational rare disease therapy lumasiran as Sanofi declines to opt-in to its development, and the US biotech prepares to commercialize its first RNAi therapeutic, pencilled in for later this year.  

Options
Choices have to be made between competing priorities. • Source: Shutterstock

More from Deals

More from Business